These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

958 related articles for article (PubMed ID: 24285764)

  • 1. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
    Kaur K; Kalra S; Kaushal S
    Clin Ther; 2014 Jul; 36(7):1074-86. PubMed ID: 25047498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
    Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
    Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
    Bannwarth B; Kostine M; Poursac N
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
    Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
    J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
    Song GG; Bae SC; Lee YH
    Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
    Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
    Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
    Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
    Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
    Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
    Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.